Dogwood Therapeutics focuses on developing innovative therapies for neurological disorders, leveraging advanced technologies to create targeted treatments. Their pipeline includes a range of products designed to address conditions such as chronic pain and neurodegenerative diseases. The company employs a proprietary platform that integrates cutting-edge research in molecular biology and pharmacology, enabling the design of therapeutics that can effectively modulate neural pathways and improve patient outcomes.

The technologies utilized by Dogwood Therapeutics emphasize precision medicine, utilizing a combination of gene therapy and small molecule approaches to enhance therapeutic efficacy. Their research is grounded in a deep understanding of the underlying mechanisms of neurological conditions, allowing for the development of treatments that are not only effective but also tailored to individual patient needs. This commitment to scientific rigor and innovation positions Dogwood Therapeutics at the forefront of the biotechnology industry, aiming to transform the landscape of neurological treatment.

United States

Dogwood is pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing the antiviral combination therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”)

Chronic pain

Pathological Conditions

Dogwood Therapeutics

Fibromyalgia

Our lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial. In this trial, IMC-1 delivered statistically significant reduction in FM related pain, fatigue, anxiety and depressive symptoms and improved overall patient health and functioning.&nbsp; IMC-1 was better tolerated placebo, as evidenced by a lower drop-out rate due to adverse events on IMC-1 as compared to placebo.

IMC-1 (famciclovir + celecoxib)

COVID-19

IMC-2 (valacyclovir and celecoxib), as a potential treatment for managing the fatigue, sleep, attention, pain, autonomic function and anxiety associated with Long COVID, otherwise known as Post-Acute Sequelae of COVID-19.&nbsp; The Company has provided Bateman Horne Center (“BHC”) with an unrestricted grant to conduct this study. BHC is a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), FM, post-viral syndromes, and related comorbidities.

IMC-2 (valacyclovir and celecoxib)

Chemotherapy-induced neuropathic pain

Neuropathic pain

Halneuron® non-opioid, Nav 1.7 inhibitor to treat the neuropathic pain associated with chemotherapy treatment.

Dogwood Therapeutics

Company Details